Homepage Top Section2

Designed based on the Ligand and Enhancer Assisted Delivery (LEAD) platform of SanegeneBio, SGB-3908 is currently in the investigational new drug application (IND)-enabling stage of development. Both Innovent

A HER3 targeting DXd antibody-drug conjugate (ADC), patritumab deruxtecan is intended for usage in patients with locally advanced or metastatic EGFR-mutated NSCLC, who have been treated with two

This vaccine is designed for preventing infections caused by the bacterial pathogen Staphylococcus aureus (S. aureus). S. aureus, a Gram-positive bacterium, affects about 30% of people, causing a

ZORYVE foam offers quick disease clearance and major reduction in itch, with nearly 80% of individuals meeting the primary efficacy endpoint of IGA Success and just more than

This drug is intended for adult patients with RCC after a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine

As per the terms of the agreement, Aldevron will get global manufacturing and commercialisation rights to Codex HiCap RNA Polymerase, and in exchange Codexis will get payments for

The alliance brings together and leverages etherna’s mRNA capabilities and LNP formulations with Almirall’s expertise in medical dermatology to speed up the discovery of new treatment options. The

The company entered into the asset purchase agreement in accordance with Regulation 596/2014/EU. Lavipharm is expected to commercialise the product on completing the relevant marketing authorisation transfer, set

AML is a fast-developing cancer originating in the blood and bone marrow, impacting myeloid cells that typically transform into different types of mature blood cells. REZLIDHIA is a